BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M)
Form 10-Q / 10-K Income Taxes Note (XBRL)
Latest, FY2025
27.8
Period ended Dec 31, 2025
Change on a year earlier
+61.6%
17.2 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.8 | +61.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 17.2 | +20.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 14.3 | +23.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 11.6 | +17.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 9.90 | +39.4% | Form 10-K (filed 2025-02-27) ↗ |
| FY2020 | Dec 31, 2020 | 7.10 | +54.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2019 | Dec 31, 2019 | 4.60 | +100.0% | Form 10-K (filed 2023-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 2.30 | +155.6% | Form 10-K (filed 2022-02-28) ↗ |
| FY2017 | Dec 31, 2017 | 0.90 | +800.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2016 | Dec 31, 2016 | 0.10 | – | Form 10-K (filed 2020-03-02) ↗ |
| FY2015 | Dec 31, 2015 | 0 | – | Form 10-K (filed 2019-02-28) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb) — ending balance ($m)
- UTB Additions — Current Year Tax Positions ($M)4.60 · FY2025
- UTB Additions — Prior Year Tax Positions ($M)6 · FY2025
- UTB Reductions — Prior Year Tax Positions ($M)0 · FY2025
- UTB Reductions — Lapse of Statute of Limitations ($M)0 · FY2025
- Deferred Income Tax Liabilities, Net ($M)53.2 · FY2025
- Deferred Tax Assets Valuation Allowance ($M)3,648 · FY2025
- Effective Income Tax Rate (%)31.2% · FY2025
- Income Taxes Paid, Net ($M)101 · FY2025
- Noncurrent Value-Added Tax (VAT) Receivable ($M)3.50 · FY2025
- PRC Subsidiaries Restricted Net Assets ($M)2,012 · FY2025
Cite this data
StockData. (2026). BeOne Medicines Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/utb_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.